

Supplementary Information

Pistacia vera L. oleoresin and levofloxacin is a synergistic combination against resistant *Helicobacter pylori* strains

Silvia Di Lodovico¹, Edoardo Napoli², Emanuela Di Campi¹, Paola Di Fermo¹, Davide Gentile², Giuseppe Ruberto², Antonia Nostro³, Emanuela Marini⁴, Luigina Cellini¹ & Mara Di Giulio^{1*}

¹Department of Pharmacy, “G. d’Annunzio” University Chieti-Pescara, Chieti, Italy. ²Institute of Biomolecular Chemistry, National Research Council ICB-CNR, Catania, Italy. ³Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy. ⁴Unit of Microbiology, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.

*Correspondence should be addressed to M.D.G. (email: mara.digiulio@unich.it) Tel: +390871 3554579, Fax: +390871 3554562

1 **Table S1** Antimicrobial susceptibility panel of *H. pylori* clinical strains used in this study


<i>H. pylori</i>	Antimicrobials*									2
	CLA	MET	LVX	MOXI	CIP	RIF	TET	AMP	AMOX ³	
11F/11	R	S	R	R	R	S	S	S	S	4
2A/12**	R	R	R	R	R	S	S	S	S	5
3F/12	R	S	R	R	R	S	S	S	S	6
4A/12	R	S	R	S	S	S	S	S	S	7
7A/12	S	S	R	R	R	S	S	S	S	8
9A/12	R	S	R	R	R	S	S	S	S	9
12F/12	R	S	R	R	R	S	S	S	S	10
13A/12	R	S	R	R	R	S	S	S	S	11
1F/13	S	S	R	R	S	S	S	S	S	12
3F/13	R	S	R	R	R	S	S	S	S	13
4A/13**	R	R	R	R	R	S	S	S	S	14
5A/13**	R	R	R	R	R	S	S	S	S	15
10A/13**	R	R	R	R	R	S	S	S	S	16
13A/13**	R	R	R	R	R	S	S	S	S	17
20A/13	R	S	R	R	S	S	S	S	S	18
23A/13	R	S	R	R	R	S	S	S	S	19
24F/13	R	S	R	R	R	S	S	S	S	20
25F/13	R	S	R	R	R	S	S	S	S	21
26A/13**	R	R	R	R	R	S	S	S	S	22
5F/14	S	S	R	R	R	S	S	S	S	23
10A/14**	R	R	R	R	R	S	S	S	S	24
29A/14	R	S	R	R	R	S	S	S	S	25
3F/15	R	S	R	R	R	S	S	S	S	26
4A/15	S	S	R	R	R	S	S	S	S	27
8F/15	R	S	R	R	R	S	S	S	S	28
30A/15**	R	R	R	R	R	S	S	S	S	29
1A/16	R	S	R	R	R	S	S	S	S	30
5A/16	R	S	R	R	R	S	S	S	S	31
7F/16**	R	R	R	R	R	S	S	S	S	32
14A/16	R	S	R	S	S	S	S	S	S	33
9F/13	S	S	S	S	S	S	S	S	S	34
ATCC 43629	S	S	S	S	S	S	S	S	S	

35 *Abbreviations: CLA, clarithromycin; MET, metronidazole; LVX, levofloxacin, MOXI, moxifloxacin; CIP,
36 ciprofloxacin; RIF, rifabutin; TET, tetracycline; AMP, ampicillin; AMOX, amoxicillin.

37 **Multidrug resistance (MDR) strains. MDR is defined as antimicrobial resistance shown by a strain with resistance at
38 least three antimicrobial classes [1]

1
2
3
4

Figure S1 *Pistacia vera* L. ORS toxicity in *Galleria mellonella* larvae at different concentrations (mg/kg)



5
6

Figure legend

Figure S1 *Pistacia vera* L. ORS toxicity assay in *Galleria mellonella* model. Kaplan-Meier survival curves of *G. mellonella* after treatment with 1000, 500, 250, 125, 62.5 mg/kg of *P. vera* L. ORS.

10
11

References

- 12
13 1. Magiorakos, A. P. *et al.* Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18(3), 268–281, <http://doi:10.1111/j.1469-0691.2011.03570.x> (2011).
14
15
16
17